No quarterly revenue total was found in ANEBULO PHARMACEUTICALS, INC.'s SEC filings.
Anebulo Pharmaceuticals, Inc. (ANEB) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-2.00M
+18.8% vs year-ago quarter
Operating cash flow
$-1.31M
+6.6% vs year-ago quarter
Free cash flow
—
EPS
$-0.05
+44.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
40.78M
-0.7% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANEB (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Lakeway, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815974
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
Q3 FY2025 Mar 31, 2025 |
Q2 FY2025 Dec 31, 2024 |
|---|---|---|---|---|---|
| Operating income | -$2.6M | -$2.3M | -$2.3M | -$1.9M | -$2.6M |
| Net income | -$2.0M | -$2.2M | -$2.1M | -$1.7M | -$2.5M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.05 | -$0.04 | -$0.09 |
| Operating cash flow | -$1.3M | -$1.3M | -$1.7M | -$1.6M | -$1.4M |
| Total assets | $9.4M | $10.7M | $12.1M | $14.0M | $15.8M |
| Total liabilities | $1.5M | $963,821 | $487,688 | $546,032 | $878,799 |
| Stockholders' equity | $7.9M | $9.7M | $11.7M | $13.5M | $15.0M |
| Cash and investments | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Feb 12, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 12, 2026 | Feb 12, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Feb 6, 2026 | Feb 5, 2026 |
| 8-K |
Current report
Other events
|
Jan 29, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Other events
|
Jan 27, 2026 | Jan 26, 2026 |
| 8-K |
Current report
Other events
|
Dec 22, 2025 | Dec 22, 2025 |
All 204 Anebulo Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.